$384 Million is the total value of DAFNA Capital Management LLC's 94 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | STEREOTAXIS INC | $51,028,000 | -39.8% | 13,680,554 | 0.0% | 13.30% | -37.7% | |
| DXCM | DEXCOM INC | $9,279,000 | -4.7% | 18,138 | 0.0% | 2.42% | -1.3% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $7,843,000 | +10.1% | 83,655 | 0.0% | 2.04% | +14.1% | |
| MORF | MORPHIC HLDG INC | $7,286,000 | -15.3% | 181,467 | 0.0% | 1.90% | -12.2% | |
| CSII | CARDIOVASCULAR SYS INC | $6,486,000 | +20.3% | 286,988 | 0.0% | 1.69% | +24.7% | |
| SAGE | SAGE THERAPEUTICS INC | $5,968,000 | -22.2% | 180,306 | 0.0% | 1.56% | -19.4% | |
| NTUS | NATUS MEDICAL INC | $5,010,000 | +10.7% | 190,635 | 0.0% | 1.30% | +14.7% | |
| ATRC | ATRICURE INC | $4,730,000 | -5.6% | 72,029 | 0.0% | 1.23% | -2.1% | |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,891,000 | +0.8% | 4,000,000 | 0.0% | 1.01% | +4.4% | ||
| ARAY | ACCURAY INC | $3,117,000 | -30.6% | 941,800 | 0.0% | 0.81% | -28.1% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $2,810,000 | +11.4% | 190,663 | 0.0% | 0.73% | +15.5% | |
| GLPG | GALAPAGOS NVspon adr | $2,647,000 | +12.5% | 42,675 | 0.0% | 0.69% | +16.6% | |
| AXGN | AXOGEN INC | $2,637,000 | -15.3% | 332,103 | 0.0% | 0.69% | -12.3% | |
| AERI | AERIE PHARMACEUTICALS INC | $2,630,000 | +29.6% | 289,040 | 0.0% | 0.68% | +34.3% | |
| AFMD | AFFIMED N V | $2,497,000 | -20.8% | 571,282 | 0.0% | 0.65% | -17.9% | |
| FSTX | F-STAR THERAPEUTICS INC | $2,463,000 | -29.3% | 693,785 | 0.0% | 0.64% | -26.7% | |
| ATHA | ATHIRA PHARMA INC | $2,173,000 | +3.6% | 160,983 | 0.0% | 0.57% | +7.2% | |
| BWAY | BRAINSWAY LTDsponsored ads | $1,746,000 | +13.4% | 200,000 | 0.0% | 0.46% | +17.6% | |
| RDUS | RADIUS HEALTH INC | $1,695,000 | +27.6% | 191,978 | 0.0% | 0.44% | +32.3% | |
| COGT | COGENT BIOSCIENCES INC | $1,674,000 | -12.7% | 223,554 | 0.0% | 0.44% | -9.5% | |
| RGLS | REGULUS THERAPEUTICS INC | $1,656,000 | -5.4% | 5,555,555 | 0.0% | 0.43% | -1.8% | |
| AERIE PHARMACEUTICALS INCnote 1.500%10/0 | $1,345,000 | +8.2% | 1,500,000 | 0.0% | 0.35% | +11.8% | ||
| VKTX | VIKING THERAPEUTICS INC | $1,342,000 | -34.8% | 447,400 | 0.0% | 0.35% | -32.4% | |
| STIM | NEURONETICS INC | $951,000 | -32.0% | 313,717 | 0.0% | 0.25% | -29.5% | |
| NXTC | NEXTCURE INC | $912,000 | -19.0% | 187,696 | 0.0% | 0.24% | -15.9% | |
| WVE | WAVE LIFE SCIENCES LTD | $780,000 | -36.3% | 390,161 | 0.0% | 0.20% | -34.1% | |
| LVTX | LAVA THERAPEUTICS NV | $613,000 | -20.0% | 139,332 | 0.0% | 0.16% | -17.1% | |
| HARP | HARPOON THERAPEUTICS INC | $523,000 | -34.1% | 105,163 | 0.0% | 0.14% | -32.0% | |
| PHAS | PHASEBIO PHARMACEUTICALS INC | $500,000 | -49.4% | 378,611 | 0.0% | 0.13% | -47.6% | |
| INGN | INOGEN INC | $486,000 | -4.7% | 15,000 | 0.0% | 0.13% | -0.8% | |
| SCYX | SCYNEXIS INC | $474,000 | -35.9% | 121,242 | 0.0% | 0.12% | -33.3% | |
| MASI | MASIMO CORP | $437,000 | -50.2% | 3,000 | 0.0% | 0.11% | -48.4% | |
| CMPX | COMPASS THERAPEUTICS INC | $269,000 | -56.8% | 196,091 | 0.0% | 0.07% | -55.1% | |
| SRGA | SURGALIGN HOLDINGS INC | $176,000 | -57.6% | 579,710 | 0.0% | 0.05% | -55.8% | |
| ANNX | ANNEXON INC | $84,000 | -76.3% | 30,796 | 0.0% | 0.02% | -75.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.